| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Oncology, Markers, Clinical Correlates |
Departments of Pharmacology and Toxicology [St. S., M. H., V. H.], Neurosurgery [S. U. P., R. F.], Obstetrics and Gynecology [So. S.], and Neuropathology [K. D.], Otto-von-Guericke-University, 39120 Magdeburg, Germany
Meningioma is one of a variety of human tumors that exhibit a very high density of somatostatin receptors and in many cases show a true positive somatostatin receptor scintigraphy. However, the level of expression of individual somatostatin receptor proteins in meningioma has not been investigated. We have recently developed a panel of somatostatin receptor subtype-specific antibodies that effectively stain formalin-fixed, paraffin-embedded tumor tissue (S. Schulz et al., Clin. Cancer Res., 4: 2047–2052, 1998). In the present study, we have used these antibodies to determine the somatostatin receptor status of 40 randomly selected meningiomas. Immunoreactive staining for all somatostatin receptors was clearly located at the plasma membrane of the tumor cells and completely blocked with antigenic peptide. The vast majority of tumors (29 cases; 70%) were positive for sst2A immunoreactivity; among these, 20 (69%) tumors showed high levels of sst2A immunoreactivity. In contrast, all other somatostatin receptors were only detected sporadically, and none of these cases revealed a particularly strong staining. However, it is uncertain to what extent somatostatin receptor-immunoreactive staining intensity may translate into somatostatin receptor protein expression on the tumor cells. Therefore, in a prospective study, 16 surgically removed meningiomas were collected, and the level of sst2A expression was determined using Western blot analysis. Whereas sst2A was readily detectable as a broad band migrating at Mr 70,000 in 12 (75%) of these tumors, 8 tumors (50%) showed particularly high levels of immunoreactive sst2A receptors. There was an excellent correlation (P < 0.001) between the level of sst2A protein expression detected in Western blots and the sst2A- immunoreactive staining seen in tissue sections. Thus, the frequent overexpression of the sst2A receptor may explain the high tracer uptake often observed in meningioma patients during somatostatin receptor scintigraphy. Moreover, this simple immunohistochemical method could prove useful in identifying those cases of recurrent disease that may possibly respond to therapy with sst2-selective agonists.
This article has been cited by other articles:
|
|
 |
|
  S. Bhandari, N. Watson, E. Long, S. Sharpe, W. Zhong, S.-Z. Xu, and S. L. Atkin Expression of Somatostatin and Somatostatin Receptor Subtypes 1-5 in Human Normal and Diseased Kidney J. Histochem. Cytochem., August 1, 2008; 56(8): 733 - 743. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Plockinger, S. Albrecht, C. Mawrin, W. Saeger, M. Buchfelder, S. Petersenn, and S. Schulz Selective Loss of Somatostatin Receptor 2 in Octreotide-Resistant Growth Hormone-Secreting Adenomas J. Clin. Endocrinol. Metab., April 1, 2008; 93(4): 1203 - 1210. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. C. Chamberlain, M. J. Glantz, and C. E. Fadul Recurrent meningioma: Salvage therapy with long-acting somatostatin analogue Neurology, September 4, 2007; 69(10): 969 - 973. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Tulipano and S. Schulz Novel insights in somatostatin receptor physiology Eur. J. Endocrinol., April 1, 2007; 156(suppl_1): S3 - S11. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Schulz, C. Rocken, M. P A Ebert, and S. Schulz Immunocytochemical identification of low-affinity NTS2 neurotensin receptors in parietal cells of human gastric mucosa. J. Endocrinol., October 1, 2006; 191(1): 121 - 128. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Schulz, R. Stumm, C. Rocken, C. Mawrin, and S. Schulz Immunolocalization of Full-length NK1 Tachykinin Receptors in Human Tumors J. Histochem. Cytochem., September 1, 2006; 54(9): 1015 - 1020. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Schulz, C. Rocken, C. Mawrin, and S. Schulz Immunohistochemical Localization of CCK1 Cholecystokinin Receptors in Normal and Neoplastic Human Tissues J. Clin. Endocrinol. Metab., November 1, 2005; 90(11): 6149 - 6155. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Henze, A. Dimitrakopoulou-Strauss, S. Milker-Zabel, J. Schuhmacher, L. G. Strauss, J. Doll, H. R. Macke, M. Eisenhut, J. Debus, and U. Haberkorn Characterization of 68Ga-DOTA-D-Phe1-Tyr3-Octreotide Kinetics in Patients with Meningiomas J. Nucl. Med., May 1, 2005; 46(5): 763 - 769. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Schulz, C. Rocken, C. Mawrin, W. Weise, V. Hollt, and S. Schulz Immunocytochemical Identification of VPAC1, VPAC2, and PAC1 Receptors in Normal and Neoplastic Human Tissues with Subtype-Specific Antibodies Clin. Cancer Res., December 15, 2004; 10(24): 8235 - 8242. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Tulipano, R. Stumm, M. Pfeiffer, H.-J. Kreienkamp, V. Hollt, and S. Schulz Differential {beta}-Arrestin Trafficking and Endosomal Sorting of Somatostatin Receptor Subtypes J. Biol. Chem., May 14, 2004; 279(20): 21374 - 21382. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Vasilaki, T. Papadaki, G. Notas, G. Kolios, N. Mastrodimou, D. Hoyer, M. Tsilimbaris, E. Kouroumalis, I. Pallikaris, and K. Thermos Effect of Somatostatin on Nitric Oxide Production in Human Retinal Pigment Epithelium Cell Cultures Invest. Ophthalmol. Vis. Sci., May 1, 2004; 45(5): 1499 - 1506. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N D Stafford, L T Condon, M J C Rogers, L Helboe, D A Crooks, and S L Atkin The immunohistochemical localisation of somatostatin receptors 1, 2, 3, and 5 in acoustic neuromas J. Clin. Pathol., February 1, 2004; 57(2): 168 - 171. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Duet, E. Sauvaget, B. Petelle, N. Rizzo, J.-P. Guichard, M. Wassef, J. Le Cloirec, P. Herman, and P. Tran Ba Huy Clinical Impact of Somatostatin Receptor Scintigraphy in the Management of Paragangliomas of the Head and Neck J. Nucl. Med., November 1, 2003; 44(11): 1767 - 1774. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. Reubi Peptide Receptors as Molecular Targets for Cancer Diagnosis and Therapy Endocr. Rev., August 1, 2003; 24(4): 389 - 427. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Ardjomand, N. Ardjomand, G. Schaffler, H. Radner, and Y. El-Shabrawi Expression of Somatostatin Receptors in Uveal Melanomas Invest. Ophthalmol. Vis. Sci., March 1, 2003; 44(3): 980 - 987. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H Kulaksiz, R Eissele, D Rossler, S Schulz, V Hollt, Y Cetin, and R Arnold Identification of somatostatin receptor subtypes 1, 2A, 3, and 5 in neuroendocrine tumours with subtype specific antibodies Gut, January 1, 2002; 50(1): 52 - 60. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Pfeiffer, T. Koch, H. Schroder, M. Klutzny, S. Kirscht, H.-J. Kreienkamp, V. Hollt, and S. Schulz Homo- and Heterodimerization of Somatostatin Receptor Subtypes. INACTIVATION OF sst3 RECEPTOR FUNCTION BY HETERODIMERIZATION WITH sst2A J. Biol. Chem., April 20, 2001; 276(17): 14027 - 14036. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
